Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis | CNS Drugs
Antibody drug development: Targeting CD20 and CD3
Establishment of C20Mab‑11, a novel anti‑CD20 monoclonal antibody, for the detection of B cells
Development of Anti-CD20 Antigen-Targeting Therapies for B-cell Lymphoproliferative Malignancies - The State of the Art | Bentham Science
Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy | PNAS
An Overview of CD20 Monoclonal Antibodies Drugs- CUSABIO
The applications of anti-CD20 antibodies to treat various B cells disorders - ScienceDirect
Potential anti-CD20 mAb effector mechanisms. (A) Fc-Fc ␥ R–dependent... | Download Scientific Diagram
Mechanisms of killing by anti-CD20 monoclonal antibodies - ScienceDirect
Anti-mouse CD20 | 18B12-derived | InvivoGen
Full article: Anti-CD20 treatment for B-cell malignancies: current status and future directions
CD20 — Wikipédia
CD20 Anticorps (FITC-65085) | Proteintech
Anticorps monoclonal anti-CD20 (rituximab) dans les maladies hématologiques et les affections auto-immunes - ScienceDirect
Frontiers | Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance | Oncogene
Anti-CD20 therapies for multiple sclerosis: current status and future perspectives | Journal of Neurology
Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library
Combining schematic of different effector mechanisms of anti CD20 mAbs... | Download Scientific Diagram
Frontiers | Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
Anti-CD20 Antibody Therapy for B-Cell Lymphomas | NEJM
Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis. | Semantic Scholar
